Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2014
The purpose of this study is to prove the superiority of a 48-weeks treatment with 3.2 g/day delayed-release phosphatidylcholine (LT-02) versus placebo for the maintenance of remission in patients with ulcerative colitis (UC)
Epistemonikos ID: 47f26fd3a12199f226ca85e2b0fc7c13ba35ec79
First added on: Mar 23, 2022